[1/3]A compagny logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo

Aug 2 (Reuters) – British biopharmaceutical giant GSK (GSK.L) sued Pfizer (PFE.N) in a U.S. court on Wednesday, alleging that Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK’s patent rights in its rival RSV shot Arexvy.

In the lawsuit brought in federal court in Delaware, GSK said New York-based Pfizer’s vaccine infringes four of its patents related to the antigen its shots use to fight the respiratory disease.Advertisement · Scroll to continuePfizer said in a statement that it is "confident […]

See also  Going With the Flow: State-to-State Migration

By Donato